Sector News

Roche to close Irish site by next year, plans 132 layoffs: report

September 19, 2019
Life sciences

After successfully selling three small molecule manufacturing plants around the world, Roche was unable to find a buyer for a site in Clarecastle, Ireland. Now, it’s set to close up there and lay off 132 workers by next year, The Irish Times reports.

Roche is already in the process of a phased exit, and the drugmaker expects the process to conclude by March 2020, the newspaper reports. The company has set aside €24 million for the employees who are still working at the site, the newspaper reports, citing Roche Ireland documents. That means each worker could be in line for a €180,000 termination payment.

In 2015, Roche unveiled a massive shift of manufacturing priorities, setting out to downsize its small molecule manufacturing capacity and bolster its biologics presence. Before that, the drugmaker announced it’d spend €800 million to expand biologics capacity at sites in Germany, Switzerland and the U.S.

As part of the moves, Roche said it would cut 1,200 jobs and exit four small molecule sites around the world. Roche ultimately found buyers for its plants in the U.S., Italy and Spain, but couldn’t sell the Ireland site, and now it’s closing up shop.

The drugmaker sold its site in Spain to Recipharm, which won a long-term deal to supply Roche with solid-dose drugs and agreed to keep 200 workers at the facility. Roche used similar contract language to sell its other plants.

Roche’s bet on biologics has been paying off as the company holds a leadership position in cancer and other diseases. But it’ll face a new test as biosimilars to its three top cancer drugs hit the U.S. market, threatening $10 billion in sales. Roche executives believe the company’s newer medicines can fill the gap created by biosimilars and add some growth.

By Eric Sagonowsky

Source: Fierce Pharma

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach